Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

Duncan H. Mak,1 Wendy D. Schober,1 Wenjing Chen,1 Marina Konopleva,1,2 Jorge Cortes,2 Hagop M. Kantarjian,2 Michael Andreeff,1,2 and Bing Z. Carter1

1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, and 2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Abstract
The advent of Bcr-Abl tyrosine kinase inhibitors (TKI) has revolutionized the treatment of chronic myelogenous leukemia (CML). However, resistance evolves due to BCR-ABL mutations and other mechanisms. Furthermore, patients with blast crisis CML are less responsive and quiescent CML stem cells are insensitive to these inhibitors. We found that triptolide, a diterpenoid, at nanomolar concentrations, promoted equally significant death of KBM5 cells, a cell line derived from a Bcr-Abl–bearing blast crisis CML patient and KBM5STI571 cells, an imatinib-resistant KBM5 subline bearing the T315I mutation. Similarly, Ba/F3 cells harboring mutated BCR-ABL were as sensitive as Ba/F3Bcr-Ablp210wt cells to triptolide. Importantly, triptolide induced apoptosis in primary samples from blast crisis CML patients, who showed resistance to Bcr-Abl TKIs in vivo, with less toxicity to normal cells. Triptolide decreased X-linked inhibitor of apoptosis protein, Mcl-1, and Bcr-Abl protein levels in K562, KBM5, and KBM5STI571 cells and in cells from blast crisis CML patients. It sensitized KBM5, but not KBM5STI571, cells to imatinib. More importantly, triptolide also induced death of quiescent CD34+ CML progenitor cells, a major problem in the therapy of CML with TKIs. Collectively, these results suggest that triptolide potently induces blast crisis CML cell death independent of the cellular responses to Bcr-Abl TKIs, suggesting that triptolide could eradicate residual quiescent CML progenitor cells in TKI-treated patients and benefit TKI-resistant blast crisis CML patients. [Mol Cancer Ther 2009;8(9):2509–16]

Introduction
Chronic myelogenous leukemia (CML) is a lethal myeloproliferative disorder derived from the clonal expansion of transformed hematopoietic stem cells (1) and is characterized by the formation of the BCR-ABL fusion gene coding for a constitutively active tyrosine kinase, which is necessary and sufficient for malignant transformation (2–4). Imatinib, a Bcr-Abl tyrosine kinase inhibitor (TKI), has drastically improved the outcome of patients with CML. However, imatinib is less effective in accelerated phase and blast crisis CML patients, 45% to 90% of whom fail to respond or develop resistance within 3 to 12 months (5, 6). Resistance to TKIs develops in both chronic and advanced CML patients, which leads to the reactivation of Bcr-Abl kinase activity within leukemic cells, through either gene amplification (7–9) or mutations (10, 11). New Bcr-Abl TKIs such as nilotinib and dasatinib have been reported to overcome resistance of most mutants but not of the T315I mutant. Regardless, because these agents inhibit tyrosine kinase activity but do not affect protein expression, mutations will likely develop again. Clearly, alternative therapeutic strategies are needed for patients with advanced and TKI-resistant CML.

Further, Bcr-Abl was shown to induce DNA damage and contribute to genomic instability (14), which is believed to be responsible for promoting the transition from the benign chronic to blast phase and providing additional growth and survival advantages for blast crisis CML cells. Therefore, eliminating the Bcr-Abl protein could be an alternative approach to treating CML patients and overcoming resistance to Bcr-Abl TKIs. Several groups have worked toward the development of such strategy (15–17).

Although the majority of CML progenitors have a higher proliferative capacity than normal progenitors (18), a subpopulation of CD34+ CML progenitors is quiescent. This cell population constitutes ~0.5% of the total CD34+ compartment and is able to engraft NOD/SCID mice and to initiate leukemia, which makes it a candidate CML stem cell (19, 20). An additional problem with current therapies for CML, including TKIs, other signal transduction inhibitors, and conventional chemotherapeutic agents, is that they act by inhibiting cell proliferation and inducing apoptosis. Thus, complete cures are rare because TKIs are not effective against quiescent progenitor/stem cells (21, 22) and these cells persist even when complete hematologic and cytogenetic remissions are achieved (20). Discontinuation of therapy frequently leads to relapse of the disease (21). In vitro
Triptolide-Induced Cell Death in CML

Triptolide, a diterpenoid isolated from a Chinese herb, _Tripterygium wilfordii_ Hook f, has been shown to have anti-tumor properties by suppressing cell growth and inducing apoptosis (23–26). We recently reported that triptolide induces cell death in AML by inhibiting the RNA and protein levels of X-linked inhibitor of apoptosis protein (XIAP) and decreasing the protein level of Mcl-1 (27), two potent cellular antiapoptotic proteins. Mcl-1 was recently reported to be a Bcr-Abl targeted gene in CML cells (28). We also showed that triptolide effectively kills KBM5 and K562 cells, two blast crisis CML cell lines (27). We here examined the effect of triptolide on imatinib-resistant CML cells and CD34+ quiescent CML progenitor cells. The results show that triptolide potently kills blast crisis CML cells independent of their responses to TKIs, in agreement with a recent report by Shi et al. (29). The results also suggest that triptolide has the potential to target quiescent CD34+ CML progenitor cells.

Materials and Methods

**Cells and Cell Culture**

KBM5 (30), an imatinib-sensitive blast crisis CML cell line, and KBM5STI571, an imatinib-resistant KBM5 subline, harboring a T315I mutation (31) in the BCR-ABL gene were cultured in Iscove’s modified Dulbecco’s medium (Life Technologies). K562 cells and Ba/F3vec, Ba/F3Bcr-AblE255K, and Ba/F3Bcr-AblT315I cells (kindly provided by Dr. C. Sawyers, University of California-Los Angeles) were cultured in RPMI 1640. Both media were supplemented with 10% heat-inactivated FCS, 2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin. Medium for Ba/F3vec cells also contained 2 ng/mL mouse recombinant interleukin-3 (Pe-protech). Bone marrow or peripheral blood samples from CML patients in blast crisis were acquired after informed consent had been obtained according to institutional guidelines and in concordance with the declaration of Helsinki. Mononuclear cells from these samples were purified by Ficoll-Hypaque (Sigma) density-gradient centrifugation and cultured in the same medium as K562 cells.

**Cell Viability Assay**

CML cells from either cell lines (0.2 × 10^6/mL) or patients with CML (0.5 × 10^6/mL) and Ba/F3 cells (0.05 × 10^6/mL) were treated with triptolide (Alexis Biochemicals) for 24 or 48 h. KBM5 and KBM5STI571 cells were treated with imatinib (LC Laboratories) for 24 to 72 h. For triptolide and imatinib combination, triptolide was administered 24 h before imatinib (1 μmol/L) was added and cell death was assessed 24 h after imatinib treatment (total 48 h). Apoptotic cell death was analyzed by measuring externalized phosphatidylserine with the Annexin V-FLUOS Staining Kit (Roch Diagnostics) in combination with a vital dye: propidium iodide or 7-amino-actinomycin D, expressed as percentage of Annexin V positive/propidium iodide positive or 7-amino-actinomycin D positive for cell lines and as percentage of survival cells (Annexin V negative/propidium iodide negative) for CML patient samples of triptolide-treated cells compared with the untreated cells.

**Cell Viability of CD34+ Quiescent and Proliferating CML Cells**

Mononuclear cells (5 × 10^6/mL) from bone marrow or peripheral blood samples from patients with blast crisis CML were labeled with 1 μmol/L 5-(and 6-)carboxyfluorescein diacetate succinimidyl ester (CFSE) as described elsewhere (32) and then cultured in serum-free RPMI 1640 supplemented with growth factors (granulocyte macrophage colony-stimulating factor, 200 pg/mL; granulocyte colony-stimulating factor, 1 ng/mL; stem cell factor, 200 pg/mL; interleukin-6, 1 ng/mL) and cocultured in RPMI 1640/10% FCS with MS-5 cells, a mouse mesenchymal stromal cell line known to support primitive human progenitor and to mimic the bone marrow microenvironment (33–35). Cell proliferation was monitored by flow cytometric measurement of CFSE fluorescence intensity, which halves with each cell division. Quiescent cells were defined as those within a region of CFSE fluorescence of paraformaldehyde-fixed cells on day 0 (CFSEbright). Proliferating cells were defined as those with a fluorescent intensity less than that of the initiating cell population (CFSEdim). After culturing for 4 to 7 days, cells were treated with triptolide for 24 or 48 h and then stained with CD34-PE and Annexin V-Cy5. Apoptosis of quiescent primitive CD34+ CML cells was defined as Annexin V positivity in the CD34+CFSEbright population, whereas apoptosis of proliferating primitive CD34+ CML cells was defined as Annexin V positivity in the CD34+CFSEdim population.

**Western Blot Analysis**

XIAP, Mcl-1, and Bcr-Abl protein levels were determined by Western blot analysis as described previously (36). XIAP antibody was purchased from BD Transduction Lab, Mcl-1 antibody was from BD Pharmingen, and c-Abl antibody was from Cell Signaling Technology. Signals were detected using a PhosphorImager (Storm 860 version 4.0; Molecular Dynamics) and quantitated by ImageJ (NIH). β-Actin was included as a loading control.

**Real-time Reverse Transcription-PCR**

RNA was extracted using Trizol solution (Invitrogen) and cDNA was generated with random hexamers and AMV reverse transcriptase (Roche Applied Science) at 42°C for 1 h. Real-time PCR was done in Applied Biosystems 7900HT Fast Reverse Transcription-PCR System using SYBR Green detection method. Reaction mixture contained 0.5 μL cDNA, 0.4 μmol/L each of the forward and reverse primers, and 2× SYBR Green master mix (Applied Biosystems) in a total of 25 μL. The reaction was initiated at 95°C for 10 min followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The specificity of the PCR products was confirmed by dissociation curve analysis with ABI SDS 2.3 software. The forward/reverse primers were 5′-GAGGCTGGGATGGGTTTGT-3′ and 5′-AAAGCCACAGCGACATCTCT-3′ for Mcl-1 and...
5′-CCCAATTGCAGATTTATCAACG-3′ and 5′-TGCATGTGTCTCAGATGGCC-3′ for XIAP. 18S RNA was used as an internal control. The abundance of each transcript relative to that of 18S was calculated using the 2^ΔCt method, where ΔCt is the mean Ct of the transcript of interest minus the mean Ct of the transcript for 18S.

**Statistical Analysis**

Experiments were done three times and the results expressed as mean ± SD. For experiments with patient samples, the results were expressed as mean ± SE. Statistical significance was denoted at \( P < 0.05 \), where applicable, using Student’s t test. Triptolide concentrations that induced Annexin V positivity in 50% of cells (IC50) were calculated using Calcusyn software (Biosoft).

**Results**

**Triptolide Induces Cell Death Independent of BCR-ABL Mutations and Cellular Response to Imatinib**

We showed previously that triptolide potently induces apoptosis in various acute leukemic cells including KBM5 and K562 cells (27), two blast crisis CML cell lines. To evaluate whether triptolide is effective in imatinib-resistant CML cells, we treated KBM5 and KBM5STI571 cells with triptolide for 48 h. As shown in Fig. 1A, KBM5STI571 and KBM5 cells had similar sensitivities to triptolide. We then treated Ba/F3vec, Ba/F3Bcr-Ablp210wt, Ba/F3Bcr-AblE255K, and Ba/F3Bcr-AblT315I cells with triptolide. We found that it invariably killed Ba/F3 cells harboring either the wild-type or mutant BCR-ABL genes at 48 h (Fig. 1B). We concluded that triptolide induces cell death independent of BCR-ABL mutation status and cellular response to imatinib. Of note, CML cells with a T315I mutation in the BCR-ABL gene are resistant not only to imatinib but also to most other more potent Bcr-Abl TKIs.

**Triptolide Induces Death of Blasts from Patients with Blast Crisis CML In vitro Independent of Patients’ Responses to Imatinib and Other Bcr-Abl TKIs**

Seven samples of mononuclear cells were obtained from 6 patients with blast crisis CML and treated with triptolide in vitro. The characteristics of these patients and their in vitro responses to treatments are illustrated in Table 1.

### Table 1. Characteristics of CML patients treated with triptolide in vitro

<table>
<thead>
<tr>
<th>Patient</th>
<th>Blast (%)</th>
<th>Sample source</th>
<th>In vitro treatments and responses at the time of sampling</th>
<th>Bcr-Abl mutation status</th>
<th>Blast crisis lineage</th>
<th>In vitro triptolide treatment IC50 (nmol/L)</th>
<th>Western blot</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>49</td>
<td>Peripheral blood</td>
<td>Resistant to imatinib and nilotinib</td>
<td>M351T</td>
<td>Myeloid</td>
<td>32.5</td>
<td>XIAP</td>
</tr>
<tr>
<td>2</td>
<td>62</td>
<td>Peripheral blood</td>
<td>Resistant to imatinib</td>
<td>Wild-type</td>
<td>Myeloid</td>
<td>178.9</td>
<td>XIAP, Mcl-1, Bcr-Abl</td>
</tr>
<tr>
<td>3</td>
<td>80</td>
<td>Peripheral blood</td>
<td>Resistant to imatinib, nilotinib, and other therapies</td>
<td>Wild-type</td>
<td>Myeloid</td>
<td>84.1</td>
<td>—</td>
</tr>
<tr>
<td>3a</td>
<td>83</td>
<td>Bone marrow</td>
<td>—</td>
<td>Wild-type</td>
<td>—</td>
<td>87.9</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>91</td>
<td>Peripheral blood</td>
<td>Hydrea, later died</td>
<td>Wild-type</td>
<td>Myeloid</td>
<td>43.0</td>
<td>—</td>
</tr>
<tr>
<td>5</td>
<td>87</td>
<td>Peripheral blood</td>
<td>No cytogenetic remission with imatinib, dasatinib, or nilotinib</td>
<td>Wild-type</td>
<td>Myeloid</td>
<td>111.7</td>
<td>XIAP, Mcl-1, Bcr-Abl</td>
</tr>
<tr>
<td>6</td>
<td>64</td>
<td>Peripheral blood</td>
<td>Failed imatinib and other chemotherapies</td>
<td>Wild-type</td>
<td>Bi-lineage</td>
<td>206.2</td>
<td>XIAP, Mcl-1, Bcr-Abl</td>
</tr>
</tbody>
</table>

**Figure 1.** Triptolide potently induces cell death in blast crisis CML cells independent of cellular responses to imatinib. KBM5 and KBM5STI571 cells (A) and Ba/F3vec, Ba/F3Bcr-Ablp210wt, Ba/F3Bcr-AblE255K, and Ba/F3Bcr-AblT315I cells (B) were treated with various concentrations of triptolide for 48 h. C, blasts from patients with CML were treated for 24 h. Cell death was determined by Annexin V staining.
Interestingly, apart from patient 4, who had not been treated with imatinib or other TKIs, all patients were resistant to imatinib. Three of 6 patients (1, 3, and 5) were also resistant to nilotinib, a more potent Bcr-Abl TKI. In addition, patient 5 was also treated with dasatinib, a dual Bcr-Abl and Src inhibitor, but had failed to achieve a cytogenetic remission. As shown in Table 1, other than M351T mutation detected in BCR-ABL gene in patient 1, no mutations were found in other patients. Nevertheless, most of them were insensitive to TKIs in agreement with literature reports. Regardless of their response to TKIs, all samples were sensitive to triptolide in vitro. As shown in Fig. 1C and Table 1, triptolide induced significant cell death in all samples studied at 24 h, indicating that triptolide induces death of CML blast cells in vitro independent of patients’ clinical responses to imatinib and other TKIs.
Bcr-Abl TKIs. It is important to point out that, with 50 or 100 nmol/L triptolide, ∼40% or 50% of cells, respectively, lost viability in those samples, whereas our previous study showed that, at the same concentrations, >90% or ∼75% of CD34+ cells, respectively, from normal bone marrow samples were viable (27).

Triptolide Decreases Antiapoptotic XIAP and Mcl-1 as well as CML-Causative Bcr-Abl Levels

Next, we investigated the involvement of apoptosis regulators in triptolide-induced cell death in CML cells. Triptolide at 100 nmol/L decreased XIAP and Mcl-1 mRNA levels in a time-dependent manner in K562 cells (Fig. 2A). Lou and Jin (37) had reported that triptolide decreased BCR-ABL RNA levels in K562 cells. We therefore analyzed XIAP, Mcl-1, and Bcr-Abl protein levels in triptolide-treated CML cells. Results showed that triptolide indeed induced dose- and time-dependent decreases in XIAP, Mcl-1, and Bcr-Abl protein levels in K562 cells (Fig. 2B). To show that triptolide has a similar effect on imatinib-resistant cells, we measured XIAP, Mcl-1, and Bcr-Abl protein levels in triptolide-treated CML cells. Results showed that triptolide indeed induced decreases of XIAP, Mcl-1, and Bcr-Abl protein levels in both cell lines. The responses of K565 and K5M5STI571 cells to imatinib were also verified and shown in Fig. 2C. We next determined the levels of these proteins in triptolide-treated primary blast cells from CML patients and Fig. 2D shows that XIAP, Mcl-1, and Bcr-Abl protein levels decreased in a dose-dependent manner. These were the same samples that were used in the in vitro triptolide experiments shown in Fig. 1C. Because of the limited number of cells available in some samples, XIAP protein levels were determined in 4 of the 7 samples and Bcr-Abl and Mcl-1 protein levels in 3 of the 7 samples (Table 1).

Triptolide Sensitizes CML Cells to Imatinib-Induced Cell Death

Based on the observation that triptolide decreases the levels not only of antiapoptotic proteins XIAP and Mcl-1 but also of the CML-causative Bcr-Abl protein, we hypothesized that the combination of triptolide and imatinib would be more effective at inducing death in CML cells than each of the agents alone. To test this hypothesis, we treated K565 cells with both triptolide and imatinib and did not observe any sensitization. This was probably due to the fact that imatinib primarily inhibits cell growth at low concentrations and with short treatment, which diminishes the killing effect of triptolide. We then treated K565 cells with triptolide for 24 h and then added 1 μmol/L imatinib for additional 24 h. This combination treatment was more effective in inducing cell death in K565 cells (Fig. 3; IC50, 15.4 ± 0.6 compared with 24.3 ± 2.8 nmol/L for triptolide alone). Triptolide did not sensitize K5M5STI571 cells to imatinib (results not shown).

Triptolide Induces Death of Quiescent CD34+ Primitive CML Cells

To test the effect of triptolide on the viability of quiescent CD34+ CML cells, which are known to be resistant to TKIs (21, 22), we first cultured CFSE-labeled cells from 5 CML patients (Table 2) with medium supplemented with a cocktail of growth factors (patients 1 and 2) or with MS-5 stromal cells (patients 3-5) for 4 to 7 days. Cell proliferation was tracked by flow cytometric analysis of CFSE fluorescence intensity and shown in Fig. 4 (left; gated on live cells by

Table 2. Characteristics of patients with CML, whose CD34+ cells were used for testing triptolide sensitivity

<table>
<thead>
<tr>
<th>Patient</th>
<th>Source</th>
<th>Blast (%)</th>
<th>Treatment and responses at the time of sampling</th>
<th>Bcr-Abl mutation status</th>
<th>Blast crisis lineage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Peripheral blood</td>
<td>59</td>
<td>Resistant to or relapsed from various treatment including IFN, imatinib, dasatinib, fludarabine + ara-C bid, and i.v. homoharringtonine + imatinib</td>
<td>F317L</td>
<td>Myeloid</td>
</tr>
<tr>
<td>2</td>
<td>Peripheral blood</td>
<td>17</td>
<td>Resistant to various therapies including IFN + low-dose ara-C, imatinib, nilotinib, and dasatinib</td>
<td>Wild-type</td>
<td>Myeloid</td>
</tr>
<tr>
<td>3</td>
<td>Peripheral blood</td>
<td>58</td>
<td>Resistant to imatinib and nilotinib</td>
<td>F317L</td>
<td>Lymphoid</td>
</tr>
<tr>
<td>4</td>
<td>Peripheral blood</td>
<td>58</td>
<td>Achieved short hematologic remission with idarubicin + ara-C/imatinib but soon after had evidence of Philadelphia-positive chromosome, resistant to dasatinib and MK-0457</td>
<td>T315I</td>
<td>Myeloid</td>
</tr>
<tr>
<td>5</td>
<td>Bone marrow</td>
<td>60</td>
<td>Achieved hematologic response with imatinib and dasatinib, achieved and then lost cytogenetic response to dasatinib, was on bosutinib</td>
<td>V299L</td>
<td>Myeloid</td>
</tr>
</tbody>
</table>
scattering of bulk population for patient 1 who had <2% CD34+ cells and of CD34+ cells for other patients). As illustrated in Fig. 4, proliferating cells that represent the majority of blasts from all 5 patients were sensitive to triptolide, consistent with the results shown in Fig. 1C. Quiescent CD34+ cells were in general as sensitive as proliferating CD34+ cells to triptolide: in 4 of the 5 patient samples (patients 1 and 3-5), proliferating and quiescent cells responded similarly, undergoing the same degree of apoptosis. Only in cells from patient 2, quiescent CD34+ cells were resistant, whereas proliferating CD34+ cells were sensitive to triptolide. The sensitivity of CD34+ cells to triptolide was not affected by preculturing these cells with growth factors or cocultured with MS-5 cells for 4 to 7 d and then treated with triptolide for 24 or 48 h. Apoptosis in quiescent and proliferating CD34+ cells was determined using Annexin V staining and shown as % positivity of the respective populations. GF, growth factor; P, proliferating; Q, quiescent.

**Discussion**

Our study showed that triptolide potently induces apoptosis of blast crisis CML cells from both cell lines and primary patient samples independent of the BCR-ABL mutation.
status and response to imatinib and other TKIs, at least in part, by decreasing XIAP, Mcl-1, and Bcr-Abl proteins. The triptolide-induced decrease in these protein levels is likely part of the mechanism by which triptolide induces death of Bcr-Abl–expressing cells and overcomes TKI resistance. More importantly, triptolide promotes the death not only of proliferating but also of quiescent CD34+ primitive CML cells.

Generation of the Bcr-Abl fusion gene is the causative genetic defect in early-stage CML. With disease progression, additional chromosomal and molecular changes occur and blasts from patients with blast crisis CML show enhanced proliferation and survival. Hence, it is not surprising that imatinib and other TKIs are not very effective in patients with advanced CML. Triptolide decreases not only Bcr-Abl protein level but also the levels of XIAP and Mcl-1, two potent antiapoptotic proteins. These attributes of triptolide give it a distinct advantage over imatinib and other TKIs, which affect only proliferating cells, particularly in decreasing Bcr-Abl protein levels, and by lowering the apoptotic threshold and activating the apoptotic cascade. This ability of triptolide to decrease Bcr-Abl, XIAP, and Mcl-1 levels also explains why triptolide-induced cell death is independent of cellular response to imatinib or other second-generation Bcr-Abl TKIs and occurs in quiescent cells. Mcl-1 expression was reported to be dependent on BCR-ABL in CML (27, 28); therefore, the decrease in Bcr-Abl levels by triptolide may result in further decrease in Mcl-1 levels in triptolide-treated CML cells. In our experiments, Bcr-Abl protein decreased before Mcl-1 (Fig. 2B), supporting the notion that Mcl-1 is a downstream target of Bcr-Abl.

Ba/F3vec cells, the vector control without Bcr-Abl, were also killed by triptolide. These cells were cultured in a medium supplemented with interleukin-3, which activates various survival pathways of the cells. Because triptolide also induces cell death by decreasing survival proteins XIAP and Mcl-1 independent of Bcr-Abl, it is not surprising that they are sensitive to triptolide.

We have reported previously that although triptolide inhibits colony formation of normal bone marrow cells, normal CD34+ cells are less sensitive than AML blasts to triptolide (27). This is probably due to the fact that apoptotic pathways are often deregulated in leukemia cells and these cells are more than normal cells dependent on XIAP, Mcl-1, and Bcr-Abl in the case of CML, and other antiapoptotic proteins for survival, as supported by the oncogene addiction theory (38). Given the resistance of quiescent CML stem cells to most anticancer agents, the ability of triptolide to promote the death of quiescent CD34+ CML cells warrants the clinical development of this agent. It was reported that PG490-88, a water-soluble derivative of triptolide, at 0.25 mg/kg markedly decreased tumor growth and at 0.5 and 0.75 mg/kg doses caused profound tumor regression without apparent toxicities in nude mouse human tumor xenograft models (39). A decrease in WBC was reported in clinical trials with triptolide or extracts of T. wilfordii (40, 41). A phase I clinical trial with a water-soluble derivative of triptolide in solid tumors is presently ongoing; importantly, a clinical phase I trial in France has determined the maximum tolerated dose for triptolide and reported three complete remissions of 26 patients with AML (42).

The importance of the hematopoietic microenvironment in the maintenance and differentiation of hematopoietic progenitor cells has been recognized only in the past few years. Both in vivo and in vitro, the growth, survival, and differentiation of hematopoietic cells have been found to require direct contact with mesenchymal stromal cells, which produce various cytokines and chemokines (43–47). Mesenchymal stromal cells interact similarly with leukemic cells in vivo and provide a protective microenvironment that enables leukemic cells to proliferate and survive. For these reasons, a cocktail of growth factors is commonly used for the maintenance of CD34+ CML progenitor cells in vitro as was done in the current study. We found that the sensitivity of CD34+ cells to triptolide is not affected by preculturing these cells with either the cocktail (Fig. 4, patients 1 and 2) or MS-5 cells (Fig. 4, patients 3-5).

Taken together, results show that triptolide has the potential of complementing the activity of imatinib and other TKIs by effective killing bulk CML cells in blast crisis and depleting quiescent as well as proliferating CD34+ CML progenitor cells independent of their sensitivity to TKIs. Thus, triptolide could be a novel agent in patients with CML in accelerated and blast crisis, in patients not responsive to TKIs including those with the T315I mutation, and in eradicating quiescent CD34+ CML progenitor cells.

Our findings of effects of triptolide on CML are in agreement with the results of Shi et al. (29) that triptolide decreases Bcr-Abl, XIAP, and Mcl-1 protein levels in CML cell lines and our studies extend these results to primary CML samples. Importantly, we here show that triptolide sensitizes to imatinib-induced cell death and has major activity in quiescent primitive CD34+ CML progenitor cells.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Elena S. Vess, Bradley S. Tadlock, Betty L. Notzon, and Angelique L. Geehan for help with the article preparation.

References
Triptolide-Induced Cell Death in CML


12. Roche-Lestienne C, Soenen-Cornu V, Gradel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014–8.


Molecular Cancer Therapeutics

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

Duncan H. Mak, Wendy D. Schober, Wenjing Chen, et al.

Mol Cancer Ther 2009;8:2509-2516. Published OnlineFirst September 1, 2009.

Updated version
Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-09-0386

Cited articles
This article cites 45 articles, 28 of which you can access for free at: http://mct.aacrjournals.org/content/8/9/2509.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at: /content/8/9/2509.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.